[B031] Medical News
Obtain news about title, content, publish date etc.
Request Parameters
List of parameters supported by this API endpoint
| Name | Type | Example | Description |
|---|---|---|---|
Required | string | f57e970e-8f97-39b7-a6be-51846e92bee1 | News ID, obtain this through the [B045] medical news search interface |
Response Schema
Structure of the API response data
| Field Name | Type | Example | Description |
|---|---|---|---|
data | object | - | response data |
drug | array | [
{
"drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
},
{
"lang": "CN",
"name": "雷珠单抗"
}
]
}
] | Drug, Referencing "CommonDrug" |
drug_id | string | e82b83b42eba4e5ea3f26f8e06081a5a | Drug ID |
display_name | array | [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
},
{
"lang": "CN",
"name": "雷珠单抗"
}
] | Drug Name, Referencing "CommonName" |
lang | string | EN | Language |
name | string | Ranibizumab (Genentech) | Drug,Target,Organization,Disease,Country/Location,DICT,Mechanism Action Name |
tags | array | [
"Careers",
"Resume",
"BioSpace",
"advice"
] | News Tags |
title | string | Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) | News title |
author | array | [
"Thomas Fink"
] | Author |
target | array | [
{
"target_id": "1c2067e5ab054a8995f73efcfcf56207",
"short_name": [
{
"lang": "EN",
"name": "VEGF"
}
],
"display_name": [
{
"lang": "EN",
"name": "Vascular endothelial growth factor"
},
{
"lang": "CN",
"name": "血管内皮生长因子"
}
]
}
] | Target, Referencing "CommonTarget" |
target_id | string | 1c2067e5ab054a8995f73efcfcf56207 | Target ID |
short_name | array | [
{
"lang": "EN",
"name": "VEGF"
}
] | Target Short Name, Referencing "CommonName" |
display_name | array | [
{
"lang": "EN",
"name": "Vascular endothelial growth factor"
},
{
"lang": "CN",
"name": "血管内皮生长因子"
}
] | Target Full Name, Referencing "CommonName" |
channel | array | [
"company information"
] | News Channel |
content | string | The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeks\nSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreated | News content |
disease | array | [
{
"disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
"display_name": [
{
"lang": "EN",
"name": "Uveitic Macular Edema"
},
{
"lang": "CN",
"name": "葡萄膜炎黄斑水肿"
}
]
}
] | Disease, Referencing "CommonDisease" |
disease_id | string | 06a9082fe1ec4c97bea31d888b9cfdce | Disease ID |
display_name | array | [
{
"lang": "EN",
"name": "Uveitic Macular Edema"
},
{
"lang": "CN",
"name": "葡萄膜炎黄斑水肿"
}
] | Disease Name, Referencing "CommonName" |
news_id | string | f57e970e-8f97-39b7-a6be-51846e92bee1 | News ID |
post_time | integer<int64> | 1720600697798 | Post Time |
source_url | string | https://www.biospace.com/article/releases/cerevel-therapeutics-announces-publication-in-the-lancet-of-emraclidine-data-from-phase-1b-clinical-trial-in-people-living-with-schizophrenia/ | News Link |
organization | array | [
{
"display_name": [
{
"lang": "EN",
"name": "Roche Holding AG"
},
{
"lang": "CN",
"name": "罗氏"
}
],
"organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
}
] | Organization, Referencing "CommonOrganization" |
display_name | array | [
{
"lang": "EN",
"name": "Roche Holding AG"
},
{
"lang": "CN",
"name": "罗氏"
}
] | Organization Name, Referencing "CommonName" |
organization_id | string | 87bfaf037f8e60c9e25595cd98bb27e4 | Organization ID |
statusRequired | boolean | false | Status |
error_msg | string | The request parameter format is incorrect! | Error Message |
error_codeRequired | integer | 0 | Error Code |
Success Response Example
Example of a successful API response
JSON
{
"data": {
"drug": [
{
"drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"tags": [
"Careers",
"Resume",
"BioSpace",
"advice"
],
"title": "Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)",
"author": [
"Thomas Fink"
],
"target": [
{
"target_id": "1c2067e5ab054a8995f73efcfcf56207",
"short_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"channel": [
"company information"
],
"content": "The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeks\\nSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreated",
"disease": [
{
"disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
]
}
],
"news_id": "f57e970e-8f97-39b7-a6be-51846e92bee1",
"post_time": 1720600697798,
"source_url": "https://www.biospace.com/article/releases/cerevel-therapeutics-announces-publication-in-the-lancet-of-emraclidine-data-from-phase-1b-clinical-trial-in-people-living-with-schizophrenia/",
"organization": [
{
"display_name": [
{
"lang": "EN",
"name": "Ranibizumab (Genentech)"
}
],
"organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
}
]
},
"status": true,
"error_code": 0
}Error Codes
List of possible error codes returned by this endpoint
Business Errors
| Error Code | Description |
|---|---|
68300004 | Invalid parameter! |
68300005 | Search api failure! |
68300006 | Analytic basic access error! |
68300007 | Bad request! |
68300008 | Service error, please try again later! |
68300010 | The file does not comply with upload specifications! |
Platform Errors
| Error Code | Description |
|---|---|
67200001 | API call exceeds the total limit set by the platform! |
67200002 | Quota exceeds the limit! |
67200003 | Access token expired or authentication error! |
67200004 | No permission or API package quota has exceeded the limit! |
67200005 | Insufficient balance, call failed! |
67200006 | This client has expired and call failed! |
67200007 | Exceeded the call limit, call failed! |
HTTP Status Codes
| Status Code | Description |
|---|---|
0 | Success |
401 | Unauthorized |
403 | Forbidden |
404 | Not Found |